This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

Given his history, Adams could be dressing up Auxilium for a sale.

Before that happens, Adams probably has to set a course for faster growth from Xiaflex and stabilize Testim sales. Once that's done, Auxilium could be ripe for a sale. All this makes Auxilium an interesting stock to follow for the next year.

Aveo is developing the kidney cancer drug tivozanib, currently under review at the FDA with an approval decision date of July 28, 2013. Investors have been punishing the stock because of worries about the approvability of tivozanib. In a pivotal phase III study, tivozanib delayed tumor progression and demonstrated a better safety profile than Onyx Pharma's (ONXX) Nexavar, but overall survival was greater for Nexavar than tivozanib.

Aveo has tried to explain away the survival benefit conundrum, insisting that patients treated with Nexavar in the pivotal trial "crossed over" to treatment with tivozanib as well. Still, the controversy has created an overhang on the stock.

Last week, Aveo CEO Tuan Ha-Ngoc purchased 75,000 shares of Aveo stock. Three directors also bought shares, including Henri Termeer, the former CEO of Genzyme. These insiders obviously betting that the FDA will approve tivozanib.

While many companies try to explain away doubts about clinical trial results, it's rare to see executives and directors talk with their wallets by buying significant amounts of their own stock. That's what Aveo insiders have done.

It will be quite interesting to see what happens next summer when tivozanib comes up for FDA approval. Before the decision, FDA is likely to convene an advisory panel to review the pivotal trial data. The confounding survival results will definitely be debated.

Rosenblum is long Auxilium and Aveo.
Dan Rosenblum has been a full-time stock trader since 1999 after leaving a job at a publicly held medical-device company. Rosenblum joined that year and has been the online trading community's resident biotech expert ever since. Rosenblum writes the newsletter, which has outperformed the S&P 500 and the Nasdaq Biotechnology Index every year since its inception in 2006. Rosenblum lives with his wife and kids in Rockland County, New York.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AUXL $36.47 -0.16%
AVEO $0.95 0.00%
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs